Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 18/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431050 | 0.93 | — | — | |
| SCHEMBL4490324 | 0.83 | — | — | |
| SCHEMBL22157540 | 0.79 | DNM1 (0.44) | LSS | |
| SCHEMBL14727255 | 0.79 | TSHR (0.42) | LSSPYCR1 | |
| SCHEMBL7354444 | 0.78 | LSS (0.38) | LSS | |
| SCHEMBL9805638 | 0.77 | DNM1 (0.48) | LSS | |
| SCHEMBL9805588 | 0.77 | DNM1 (0.48) | LSS | |
| SCHEMBL4484949 | 0.77 | LSS (0.40) | LSSPYCR1MEN1KMT2A | |
| SCHEMBL9805609 | 0.77 | DNM1 (0.48) | LSS | |
| SCHEMBL8775557 | 0.77 | DNM1 (0.48) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | claimed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | claimed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | claimed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | claimed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | claimed |
| EP-1451180-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | claimed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | claimed |
| US-20040034046-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | US | claimed |
| EP-1381599-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2004-01-21 | — | — | EP | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | CD4, HLA-DRB1, IL5 | LSS 2879/4885PYCR1 1079/4885MEN1 100/4885 |
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | LSS 3483/4885PYCR1 892/4885MEN1 372/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | LSS 3672/4885PYCR1 2207/4885MEN1 576/4885 |
| US-20040034046-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | LSS 1797/4885PYCR1 2085/4885MEN1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.